June 21, 2021

Phapros Launches Two New Products amidst Covid-19 Pandemic

Entering its 67th year anniversary, PT Phapros Tbk (PEHA) which is a subsidiary of PT Kimia Farma Tbk, launched two new products related to the prevention of Covid-19, namely vitamin D3 1000 IU (Pehavit) and vitamin C non-acid 500 mg which is safe for the stomach, so it is comfortable to consume for people with high stomach acid disease.

President Director of Phapros, Hadi Kardoko said that his party launched the two products as a form of preventing the transmission of Covid-19, which is now increasing in cases. "In celebration of the 67th anniversary of Phapros, we launched two vitamin products to help increase the immunity of the community in the midst of increasing Covid-19 cases, so that it can reduce the rate of transmission of Covid-19," said Hadi

He added that the launch of the new product was also an implementation of the product portfolio shift strategy due to the Covid-19 pandemic. "People's mobility is very limited, so to stay afloat we must not only rely on the travel sector with Antimo products, but also we adapt by innovating to develop products related to the prevention and treatment of Covid-19," he added.

Phapros' product shifting strategy has been paid off. At least in the first quarter of 2021, the company posted a positive performance in 2021 with an increasing net profit of 254% as well as Ebitda which also spiked by 465% (y-o-y). The financial statements of PT Phapros Tbk show convincing figures in the first quarter of 2021. Net profit for the period reached Rp7.18 billion, or increased by 254% and EBITDA reached Rp 46.82 billion, or increased by 465% compared to last year (y-o-y).

To continue improving its performance in the midst of today's challenging conditions, the Company has prepared various strategic plans, including the development of organic and inorganic businesses, as well as launching a minimum of 10 new products in the next two years. The products that will be launched are from several therapeutic classes, such as antibiotics, antidiabetics and anticholesterol which are classified as first line therapy products, thus adding to the completeness of Phapros products.